CPIX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
166.5K
-98.2%
9.1M
-33.2%
13.7M
+65.0%
8.3M
+2077.6%
380.8K
Cost of Revenue
0
-100.0%
1.9M
-13.7%
2.2M
+126.7%
988.8K
0
Gross Profit
166.5K
-97.7%
7.2M
-37.1%
11.4M
+56.6%
7.3M
+1818.0%
380.8K
Operating Expenses
3.3M
-67.8%
10.3M
-19.4%
12.8M
+38.2%
9.3M
+164.8%
3.5M
R&D
772.2K
-47.1%
1.5M
-5.9%
1.5M
+23.6%
1.3M
+49.7%
837.4K
SG&A
2.5M
-66.6%
7.6M
-25.6%
10.2M
+46.2%
7.0M
+163.7%
2.7M
Operating Income
-3160461
-1.0%
-3129292
-128.2%
-1371202
+30.2%
-1965260
+37.0%
-3119519
EBITDA
-4365125
-135.6%
-1853009
-462.7%
-329307
+64.5%
-927456
+77.2%
-4073334
Net Income
-4274430
-30.0%
-3287051
-130.1%
-1428642
+26.7%
-1949046
-165.1%
-735207
EPS (Basic)
$-0.29
-31.8%
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
-160.0%
$-0.05
EPS (Diluted)
$-0.29
-31.8%
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
-160.0%
$-0.05
Shares (Diluted)
15.0M
+0.1%
15.0M
+5.1%
14.2M
-4.8%
15.0M
-0.0%
15.0M
Cumberland Pharmaceuticals (CPIX) โ€” Financials